These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16199161)

  • 21. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment with oral agents for breast cancer].
    Ito Y
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1203-7. PubMed ID: 20647699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors: implications for optimal postoperative adjuvant chemotherapy.
    Uchida J; Okabe H; Nakano K; Fujioka A; Saito H; Sugimoto Y; Oka T; Fukushima M
    Oncol Rep; 2007 Aug; 18(2):313-9. PubMed ID: 17611650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.
    Bertolini F; Paul S; Mancuso P; Monestiroli S; Gobbi A; Shaked Y; Kerbel RS
    Cancer Res; 2003 Aug; 63(15):4342-6. PubMed ID: 12907602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
    Emmenegger U; Man S; Shaked Y; Francia G; Wong JW; Hicklin DJ; Kerbel RS
    Cancer Res; 2004 Jun; 64(11):3994-4000. PubMed ID: 15173013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells.
    Bertolini F
    Cancer Metastasis Rev; 2008 Mar; 27(1):95-101. PubMed ID: 18066648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endogenous angiogenesis inhibitors.
    Folkman J
    APMIS; 2004; 112(7-8):496-507. PubMed ID: 15563312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microtubule-targeting agents in angiogenesis: where do we stand?
    Pasquier E; Honoré S; Braguer D
    Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
    Tsakonas G; Kosmas C
    J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
    Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
    Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
    Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance in chemotherapy for breast cancer.
    Saeki T; Tsuruo T; Sato W; Nishikawsa K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metronomic chemotherapy: teaching old drugs new tricks?
    Vogelzang N
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217
    [No Abstract]   [Full Text] [Related]  

  • 39. Maintenance treatment in metastatic breast cancer.
    Sánchez-Muñoz A; Pérez-Ruiz E; Ribelles N; Márquez A; Alba E
    Expert Rev Anticancer Ther; 2008 Dec; 8(12):1907-12. PubMed ID: 19046111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary systemic therapy of breast cancer.
    Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
    Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.